34 results on '"Chapple C"'
Search Results
2. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies
3. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
4. Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial
5. Contemporary issues with pharmacotherapy for lower urinary tract symptoms
6. Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences?
7. The burden of urgency urinary incontinence on health and wellbeing
8. Current issues in managing men with lower urinary tract symptoms in primary care
9. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis
10. Lower urinary tract symptoms revisited
11. Editorial comment regarding diagnostic value of International Prostate Symptom Score (IPSS) voiding-to-storage subscore ratio in male lower urinary tract symptoms
12. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review
13. New once-daily formulation for trospium in overactive bladder
14. Antimuscarinic agents in elderly people
15. Assessing patientsʼ descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research
16. Nocturia: not just the elderly
17. Nocturia and the danger of falls
18. A stepwise approach to the treatment of the enlarged prostrate
19. Urinary urgency – translating the evidence base into daily clinical practice
20. Overactive Bladder and Continence Guidelines: implementation, inaction or frustration?
21. Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK
22. The emerging role of intravesical botulinum toxin therapy in idiopathic detrusor overactivity
23. Botulinum toxin injection therapy in the management of lower urinary tract dysfunction
24. Overactive bladder: the importance of new guidance
25. Solifenacin significantly improves all symptoms of overactive bladder syndrome
26. Nocturia: morbidity and management in adults
27. Towards patient-driven criteria in overactive bladder management
28. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies
29. Safety and tolerability of the β 3 ‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial
30. Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences?
31. Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
32. Which drugs are best for overactive bladder? From patients' expectations to physicians' decisions.
33. Night-time voids, level of bother and sleep characteristics in a non-patient population of wearable devices users.
34. Contemporary therapy for overactive bladder.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.